An artificial pancreas developed at the University of Virginia Center for Diabetes Technology improves blood sugar control for people ages 2 to 72 with type 1 diabetes, according to a new combined analysis of three clinical trials.
Across the three trials, participants using the artificial pancreas spent an average of 2.8 more hours per day in their target blood sugar range compared with participants in control groups who used standard methods for managing their blood sugar.
Manufactured by Tandem Diabetes Care and sold as the Control-IQ system, the artificial pancreas is a diabetes-management solution that automatically monitors and regulates blood glucose. The device has an insulin pump that uses advanced control algorithms based on the person’s glucose-monitoring information to adjust the insulin dose as needed. The U.S. Food and Drug Administration has approved the system for people ages 6 and older with type 1 diabetes.
It is clear from these results, which are consistent with real-life data from thousands of current Control-IQ technology users, that this technology should be strongly considered as an option for anyone living with type 1 diabetes. —Boris Kovatchev, PhD, director of the UVA Center for Diabetes Technology
Read full press release in the UVA Health Newsroom.